XML 73 R51.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaboration and Other Agreements, Pfizer (Details)
 1 Months Ended 12 Months Ended
Oct. 31, 2010
USD ($)
Dec. 31, 2015
USD ($)
Molecule
Program
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Collaboration and Other Agreements [Line Items]        
Deferred revenue included in current liabilities   $ 5,866,000 $ 14,248,000  
Pfizer [Member]        
Collaboration and Other Agreements [Line Items]        
Collaboration agreement date   October 2010    
Period of agreement   3 years    
Commercialization of molecules | Molecule   2    
Nonrefundable upfront payment $ 5,000,000      
DART program | Program   1    
Research obligation completion date   January 2014    
Term of the agreement   January 2014    
Recognized revenue under agreement   $ 500,000 100,000 $ 3,500,000
Milestone achieved   500,000    
Deferred revenue included in current liabilities   0 $ 0  
Potential Pre-clinical and Clinical Milestone Payments Under Agreement   17,000,000    
Potential Sales Milestone Payments Under Agreement   $ 195,000,000